681 Recruiting Trials

Clinical Trials
for Cancer in Massachusetts

681 clinical trials for Cancer are currently recruiting participants at study sites in Massachusetts. Study-related care is provided at no cost.

681
Recruiting trials
267
Study sites
43
Cities
329
Industry-sponsored
251
Phase 2
136
Phase 3

Cancer clinical trials in Massachusetts: what to expect

Cancer is the single largest area of clinical research, and nearly every recruiting cancer trial is written for one cancer type at one stage. Most test a new drug or combination against the current standard treatment: targeted medicines matched to a mutation found in the tumor, immunotherapies that help the immune system recognize cancer cells, antibody-drug conjugates and cell therapies. Others study surgery and radiation techniques, ways to reduce side effects, and screening or prevention in people at higher risk.

In Massachusetts, recruiting cancer studies are concentrated in Boston, Worcester, Burlington and Springfield, with sites in 39 other cities. 329 of the 681 are run by a drug or device company, which usually means a larger study with travel reimbursement; the rest are academic or hospital-led.

Who cancer trials usually look for

Every listing names the cancer type and stage it enrolls, and most also state how many earlier treatments you may have had: some are for people newly diagnosed, many are for cancer that has come back or spread after a first treatment stopped working. Targeted-therapy trials require a specific result on tumor testing, which the site can arrange if it has not been done. Trials generally ask that you are well enough for daily activity (a "performance status" the doctor scores), that blood counts and liver and kidney function are adequate, and that a few weeks have passed since your last treatment.

Having advanced or metastatic cancer does not rule you out. A large share of recruiting trials are designed specifically for it.

What taking part involves

Screening reviews your pathology and scans, often with new blood work and sometimes a fresh biopsy. Treatment then follows a cycle, typically every two or three weeks, with scans every six to twelve weeks to measure the response. Early-phase trials have more frequent visits at the start. The study drug and study-specific tests are provided at no cost; standard care that you would receive anyway is usually billed to insurance as normal. A placebo on its own is rare in cancer trials: when there is one, it is added to the standard treatment, and the consent form says so.

Questions worth asking the study team

Whether the trial is randomized and what the comparison treatment is; what happens if the cancer grows during the study; whether you can keep receiving the drug afterward if it is working; how the trial fits with the plan your own oncologist has suggested; and what travel or lodging support is offered. Your oncologist can also refer you directly.

Showing 20 of 681 recruiting Cancer trials in Massachusetts

Pan Tumor Rollover Study
PHASE2 Huntsville, Alabama +4 sites NCT03899155
This trial is looking for patients with cancer who have had a good response to previous treatments. Participants will continue receiving nivolumab alone or in combination with other cancer therapies to study long-term safety.
Recruiting
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
PHASE1 Boston, Massachusetts +4 sites NCT03686124
This trial is looking for patients with certain types of cancer that keep coming back or do not respond to standard treatments. Participants will receive the study treatment IMA203/IMA203CD8, either alone or with nivolumab.
Recruiting
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
PHASE1 Boston, Massachusetts +3 sites NCT07578571
This trial is looking for people with advanced solid tumors that cannot be removed with surgery. Participants will receive a drug called IM-1617 to see how safe and effective it is.
Recruiting
On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety
NA Boston, Massachusetts NCT07305740
This trial is looking for adult cancer survivors who are dealing with significant anxiety. Participants will engage in an online program to learn coping strategies based on proven therapy techniques.
Recruiting
A Dyadic Intervention for Young Adult Patients With Cancer and Their Partner Caregivers
NA Boston, Massachusetts +3 sites NCT06172907
This trial is looking for young adults with cancer and their partners to join a program that helps improve coping skills and support their relationship. Participants will either be receiving cancer treatment or have recently completed it.
Recruiting
Communicating Uncertainties Associated With the Benefits and Risks of New Cancer Drugs
NA Boston, Massachusetts NCT06997185
This trial is looking for adults in the U.S. who can share their thoughts on how new cancer drugs are communicated to them. Participants will help researchers understand how to better convey information about these drugs.
Recruiting
Childhood Cancer Survivor Study
N/A Birmingham, Alabama +4 sites NCT01120353
This trial is looking for childhood cancer survivors who were diagnosed before age 21 and survived for at least five years. Participants will be followed to understand the long-term effects of their cancer treatments.
Recruiting
Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
N/A Burlington, Massachusetts NCT00872495
This trial is looking for patients who are having surgery related to bladder cancer or have no known bladder cancer. Participants will provide urine samples to see if certain tests can help detect cancer and predict its behavior.
Recruiting
Integrated Cancer Repository for Cancer Research
N/A Greenwood Village, Colorado +4 sites NCT02012699
This trial is looking for adults who have a history of cancer, are at risk for developing cancer, or are healthy individuals. Participants will provide consent and may help advance cancer research by sharing data and samples.
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
PHASE3 Birmingham, Alabama +4 sites NCT06901531
This trial is looking for adults with advanced stomach or gastroesophageal junction cancer. Participants will receive a combination of zolbetuximab, pembrolizumab, and chemotherapy, or a placebo with pembrolizumab and chemotherapy to see how well it works.
Recruiting
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
PHASE3 Birmingham, Alabama +4 sites NCT04928846
This trial is looking for adults with a type of lung cancer who have already had treatment. Participants will receive either telisotuzumab vedotin or docetaxel through an IV every couple of weeks to see how well they work and how safe they are.
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
PHASE3 Birmingham, Alabama +4 sites NCT05827081
This trial is looking for adults with early breast cancer that is hormone receptor positive and HER2 negative. If you join, you will receive ribociclib along with standard hormone therapy to see how effective this combination is.
Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
PHASE3 Birmingham, Alabama +4 sites NCT06058377
This trial is looking for women with hormone receptor positive, HER2 negative stage II-III breast cancer. Participants will receive standard chemotherapy along with an immunotherapy drug called durvalumab to see if it helps prevent cancer from coming back.
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
PHASE3 Anchorage, Alaska +4 sites NCT07062965
This trial is looking for people with HR-positive, HER2-negative advanced breast cancer that has worsened after previous treatment. Participants will receive the study medicine PF-07248144 along with their normal treatment options to see how well they work together.
Recruiting
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
PHASE3 Cerritos, California +4 sites NCT07217704
This trial is looking for adults with gastric, esophageal, or gastroesophageal cancer who are evaluating their treatment options. Participants will receive a PET scan with a special substance to help detect cancer spread.
Recruiting
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
PHASE3 Boston, Massachusetts +4 sites NCT07419295
This trial is looking for people with bladder cancer that has spread or got worse after previous treatments. Participants will receive a new treatment called sacituzumab tirumotecan and be compared to those receiving standard chemotherapy options.
Recruiting
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
PHASE3 Gilbert, Arizona +4 sites NCT05894239
This trial is looking for people with advanced breast cancer that is HER2-positive and has a specific mutation. Participants will take a combination of medicines after their initial treatment.
Recruiting
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
PHASE3 Anchorage, Alaska +4 sites NCT06764875
This trial is looking for individuals with advanced stomach cancer that tests positive for HER2. Participants will receive a combination of rilvegostomig, chemotherapy, and other treatments to see how well it works.
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
PHASE3 Phoenix, Arizona +4 sites NCT06170788
This trial is looking for adults with non-small cell lung cancer that is advanced and has specific characteristics. Participants will receive a combination of sacituzumab tirumotecan and pembrolizumab or pembrolizumab alone to see which treatment helps them live longer.
Recruiting

Where the Cancer studies are in Massachusetts

  • Dana-Farber Cancer Institute, Boston192 trials
  • Massachusetts General Hospital, Boston137 trials
  • Dana Farber Cancer Institute, Boston117 trials
  • Brigham and Women's Hospital, Boston74 trials
  • Beth Israel Deaconess Medical Center, Boston48 trials
  • Research Site, Boston29 trials

Counts are recruiting studies listing at least one site in Massachusetts, from ClinicalTrials.gov, refreshed every two days.

Cancer clinical trials in Massachusetts: common questions

How many Cancer clinical trials are recruiting in Massachusetts?
TrialFinder currently lists 681 recruiting Cancer clinical trials with study sites in Massachusetts. Results are updated regularly from ClinicalTrials.gov, the official U.S. registry of clinical studies.
Where are Cancer clinical trials located in Massachusetts?
Study sites for the Cancer trials listed on this page include Boston, Burlington. Each trial page lists every participating site with contact details, so you can find the location closest to you.
Do I need insurance to join a Cancer clinical trial in Massachusetts?
No. Study-related care is covered by the trial sponsor at no cost to participants, including the study treatment, required lab tests and study visits. Many Cancer trials in Massachusetts also compensate participants for time and travel. Health insurance is not required to search or enroll.
How do I qualify for a Cancer clinical trial in Massachusetts?
Each study sets its own criteria based on age, Cancer diagnosis details, prior treatments, current medications and general health. The fastest way to find out is to contact a research site directly — most will pre-screen you by phone in 10 to 15 minutes at no charge. You can also create a free TrialFinder profile to be matched automatically.
Will I get a placebo instead of cancer treatment?
Almost never. Cancer trials compare a new treatment with the current standard treatment, or add the study drug to standard treatment. When a placebo is used it is on top of standard care, and the consent form states this before you decide.
Can I join a cancer trial if my cancer has spread?
Yes. Many recruiting cancer trials are written for advanced or metastatic disease, including people whose earlier treatments have stopped working. The listing states the stage and prior treatments it accepts.
Do I have to stop my current cancer treatment to join a trial?
It depends on the trial. Some enroll people whose current treatment has stopped working, some add the study drug to the treatment you are on, and some are for people who have not started treatment yet. Ask the study team before changing anything.
Are Clinical Trials Safe? What Patients Should Know
How clinical trial safety works — phases, IRB oversight, informed consent, and your right to withdraw — plus the real risks and questions to ask.
How to Know If You Qualify for a Clinical Trial
Every trial has eligibility criteria based on diagnosis, age, and medical history. Here's how to tell if you qualify — and what to do if you're not sure.
Clinical Trials Without Insurance: What You Need to Know
Clinical trials cover the cost of study-related care, making them one of the few ways to access treatment without health insurance. Here's what's covered.
All guides →

Check Your Eligibility

Create a free profile and our AI will match you to Cancer trials near you in Massachusetts.

Get Matched — Free
No insurance required

Breast cancer trials test new chemotherapy regimens, immunotherapy combinations, targeted therapies, and early-detection methods across all stages of breast cancer.

All Cancer trials →